Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MTOR | P42345 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CDA | P32320 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138566 | 1.00 | LMNA (0.64) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL2583058 | 0.88 | LMNA (0.51) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL10890255 | 0.88 | PDE2A (0.52) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL10890263 | 0.88 | PDE2A (0.52) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL1138717 | 0.88 | LMNA (0.63) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL1138719 | 0.88 | LMNA (0.63) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL4286246 | 0.87 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL770116 | 0.87 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL9690202 | 0.87 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL2584289 | 0.87 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049338-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | FACTOR BIOSCIENCE INC (US) | 2026-02-19 | — | — | US | claimed |
| US-12384740-B2 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12357664-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS (US) | 2025-07-15 | — | — | US | claimed |
| CN-114450265-B | Cationic lipids and uses thereof | 菲克特生物科学股份有限公司 | 2024-12-24 | — | — | CN | claimed |
| US-20230373903-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | FACTOR BIOSCIENCE INC. | 2023-11-23 | — | — | US | claimed |
| US-11814333-B2 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20230323399-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | FACTOR BIOSCIENCE INC. | 2023-10-12 | — | — | US | claimed |
| US-20230304044-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | FACTOR BIOSCIENCE INC. | 2023-09-28 | — | — | US | claimed |
| US-20230193207-A1 | MESENCHYMAL STEM CELL THERAPIES | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | claimed |
| US-20230193231-A1 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | claimed |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-08-25 | — | — | US | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| JP-2002509155-A | — | — | 2002-03-26 | — | — | JP | claimed |
| EP-1047705-A2 | NUCLEOBASE OLIGOMERS | THE PERKIN-ELMER CORPORATION (US) | 2000-11-02 | — | — | EP | claimed |
| US-6063628-A | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2000-05-16 | — | — | US | claimed |
| US-6054568-A | Nucleobase oligomers | THE PERKIN-ELMER CORPORATION (US) | 2000-04-25 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1999036429-A2 | NUCLEOBASE OLIGOMERS | THE PERKIN-ELMER CORPORATION (US) | 1999-07-22 | — | — | WO | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | LMNA 3576/4885MTOR 2746/4885ALDH1A1 1365/4885 |
| US-20230323399-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | NSUN3, STING1, NFATC1 | LMNA 694/4885MTOR 3778/4885ALDH1A1 3071/4885 |
| US-20230373903-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-12384740-B2 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-20230304044-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | NSUN3, STING1, NFATC1 | LMNA 694/4885MTOR 3778/4885ALDH1A1 3071/4885 |
| US-11814333-B2 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-20260049338-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | NSUN2, RNGTT, RNMT | LMNA 333/4885MTOR 2014/4885ALDH1A1 3232/4885 |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | LMNA 3576/4885MTOR 2746/4885ALDH1A1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.